| Item 8.01. | Other Events. |
On August 26, 2024, Accelerate Diagnostics, Inc. (the "Company") received written notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with Nasdaq's minimum Market Value of Listed Securities (as defined under Nasdaq rules) requirement of $35 million for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement") as a result of the market value of the Company's common stock having closed at $35 million or more for ten consecutive business days. Accordingly, Nasdaq considers the matter relating to the Company's prior MVLS Requirement deficiency, as previously reported in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 5, 2024, now closed.
Attachments
Disclaimer
Accelerate Diagnostics Inc. published this content on 26 August 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on August 26, 2024 at 20:11:55 UTC.